SGHT (Sight Sciences) Long-Term Debt: $36.74 Mil (As of Mar. 2026)


SGHT Sight Sciences Inc SGHT
72 GF Score
Price $5.59
GF Value $4.50
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences Long-Term Debt?

Sight Sciences SGHT +2.57% 72 Long-Term Debt is $36.74 Mil as of Mar. 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.50 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Sight Sciences's Long-Term Debt for the quarter that ended in Mar. 2026 was $36.74 Mil.

Sight Sciences's quarterly Long-Term Debt increased from Sep. 2025 ($40.07 Mil) to Dec. 2025 ($40.30 Mil) but then declined from Dec. 2025 ($40.30 Mil) to Mar. 2026 ($36.74 Mil).

Sight Sciences's annual Long-Term Debt increased from Dec. 2023 ($31.71 Mil) to Dec. 2024 ($39.36 Mil) and increased from Dec. 2024 ($39.36 Mil) to Dec. 2025 ($40.30 Mil).

Sight Sciences  (NAS:SGHT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sight Sciences Long-Term Debt Related Terms

Sight Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sight Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sight Sciences Long-Term Debt Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 32.66 33.31 31.71 39.36 40.30

Sight Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.58 39.82 40.07 40.30 36.74
SGHT
72GF Score
Sight Sciences Inc SGHT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $36.74 Mil mean?
Sight Sciences (SGHT) has a Long-Term Debt of $36.74 Mil as of Mar. 2026.
Is Sight Sciences' Long-Term Debt too high?
Sight Sciences' current Long-Term Debt is $36.74 Mil. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Long-Term Debt compare to SENS and LAB?
Sight Sciences' Long-Term Debt of $36.74 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sight Sciences's current Long-Term Debt is $36.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.50, compared to a current price of $5.59 — trading 24.2% above its estimated fair value. The current Long-Term Debt is $36.74 Mil. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Long-Term Debt is $36.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.59 is trading 24.2% above its estimated GF Value™ of $4.50. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • Long-Term Debt: $36.74 Mil
  • GF Value™: $4.50 vs. price of $5.59 (24.2% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score

Get the complete analysis for SGHT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.59
Price
$4.50
GF Value